VIR vs. RXRX

In the year-to-date period, VIR achieves a 34.20% return, which is significantly lower than RXRX's 60.80% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VIR Sharpe Ratio is -0.05, which is higher than the RXRX Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of VIR and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither VIR nor RXRX has paid dividends to shareholders.

The maximum VIR drawdown since its inception was -91.89%, roughly equal to the maximum RXRX drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for VIR and RXRX. For additional features, visit the drawdowns tool.

The current volatility for Vir Biotechnology, Inc. (VIR) is 16.37%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 29.14%. This indicates that VIR experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.